Clinical Intergroup – Clinical Studies

Primary studies

TRIANGLE

Randomized, three-arm, parallel-group, open label, international phase III trial comparing six alternating courses of R-CHOP/R-DHAP (one cycle every 21 days) followed by ASCT versus the combination with ibrutinib in induction and maintenance (2 years) or the experimental arm without ASCT

Further information

MCL R2 Elderly

Efficacy of alternating immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphoma

Further information

MCL Younger - Recruiting stopped!

Efficacy of 6 courses CHOP plus Rituximab followed by myeloablative radiochemotherapy and autologous stem cell transplantation versus alternating courses of 3x CHOP and 3x DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation
Attention! Recruitment has ended for this trial!


Further information

MCL Elderly - Recruiting stopped!

Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP vs. R-FC) for elderly patients with mantle cell lymphoma not suitable for stem cell transplantation
Attention! Recruitment has ended for this trial!


Further information

Rezidivstudien

R-HAD-Studie (MCL 2005-01)

EFFICACY AND SAFETY OF RITUXIMAB, HIGH-DOSE ARA-C AND DEXAMETHASONE (R-HAD) ALONE OR IN COMBINATION WITH BORTEZOMIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA

Further information

Zevalin-Study Recruitment stopped!

Efficacy and safety of 90Y-ibritumomab tiuxetan in patients with refractory or relapsed mantle cell lymphoma after / not appropriate for autologous stem cell transplantation
Attention: This study is closed!


Further information

Literature »